Targeting delivery of lipocalin 2-engineered mesenchymal stem cells to colon cancer in order to inhibit liver metastasis in nude mice | springermedicine.com

Springer Medicine

Top

Published in:

01-08-2015 | Research Article

Targeting delivery of lipocalin 2-engineered mesenchymal stem cells to colon cancer in order to inhibit liver metastasis in nude mice

Authors: Mozhgan Dehghan Harati, Fatemeh Amiri, Fatemeh Jaleh, Ahmad Mehdipour, Mitra Dehghan Harati, Sedigheh Molaee, Marzieh Bahadori, Mohammad Ali Shokrgozar, Mohammad Ali Jalili, Mehryar Habibi Roudkenar

Published in: Tumor Biology | Issue 8/2015

Login to get access

Abstract

One of the major obstacles in cancer therapy is the lack of anticancer agent specificity to tumor tissues. The strategy of cell-based therapy is a promising therapeutic option for cancer treatment. The specific tumor-oriented migration of mesenchymal stem cells (MSCs) makes them a useful vehicle to deliver anticancer agents. In this study, we genetically manipulated bone marrow-derived mesenchymal stem cells with their lipocalin 2 (Lcn2) in order to inhibit liver metastasis of colon cancer in nude mice. Lcn2 was successfully overexpressed in transfected MSCs. The PCR results of SRY gene confirmed the presence of MSCs in cancer liver tissue. This study showed that Lcn2-engineered MSCs (MSC-Lcn2) not only inhibited liver metastasis of colon cancer but also downregulated the expression of vascular endothelial growth factor (VEGF) in the liver. Overall, MSCs by innate tropism toward cancer cells can deliver the therapeutic agent, Lcn2, and inhibit cancer metastasis. Hence, it could be a new modality for efficient targeted delivery of anticancer agent to liver metastasis.

1.

Loebinger MR, Eddaoudi A, Davies D, Janes SM. Mesenchymal stem cell delivery of TRAIL can eliminate metastatic cancer. Cancer Res. 2009;69(10):4134–42. doi:10.1158/0008-5472.CAN-08-4698.CrossRefPubMedPubMedCentral

2.

Ferlay JSI, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. GLOBOCAN. Cancer incidence and mortality worldwide: IARC CancerBase No. 11. 2012.

3.

Bird NC, Mangnall D, Majeed AW. Biology of colorectal liver metastases: a review. J Surg Oncol. 2006;94(1):68–80. doi:10.1002/jso.20558.CrossRefPubMed

4.

Dai LJ, Moniri MR, Zeng ZR, Zhou JX, Rayat J, Warnock GL. Potential implications of mesenchymal stem cells in cancer therapy. Cancer Lett. 2011;305(1):8–20. doi:10.1016/j.canlet.2011.02.012.CrossRefPubMed

5.

Sun XY, Nong J, Qin K, Warnock GL, Dai LJ. Mesenchymal stem cell-mediated cancer therapy: a dual-targeted strategy of personalized medicine. World J Stem Cells. 2011;3(11):96–103. doi:10.4252/wjsc.v3.i11.96.CrossRefPubMedPubMedCentral

6.

Schwartz CL. Long-term survivors of childhood cancer: the late effects of therapy. Oncologist. 1999;4(1):45–54.PubMed

7.

Stein KD, Syrjala KL, Andrykowski MA. Physical and psychological long-term and late effects of cancer. Cancer. 2008;112(11 Suppl):2577–92. doi:10.1002/cncr.23448.CrossRefPubMed

8.

Hu YL, Fu YH, Tabata Y, Gao JQ. Mesenchymal stem cells: a promising targeted-delivery vehicle in cancer gene therapy. J Control Release: Off J Control Release Soc. 2010;147(2):154–62. doi:10.1016/j.jconrel.2010.05.015.CrossRef

9.

Compte M, Cuesta AM, Sanchez-Martin D, Alonso-Camino V, Vicario JL, Sanz L, et al. Tumor immunotherapy using gene-modified human mesenchymal stem cells loaded into synthetic extracellular matrix scaffolds. Stem Cells. 2009;27(3):753–60. doi:10.1634/stemcells. 2008-0831.CrossRefPubMedPubMedCentral

10.

Sotiropoulou PA, Perez SA, Salagianni M, Baxevanis CN, Papamichail M. Characterization of the optimal culture conditions for clinical scale production of human mesenchymal stem cells. Stem Cells. 2006;24(2):462–71. doi:10.1634/stemcells. 2004-0331.CrossRefPubMed

11.

Studeny M, Marini FC, Champlin RE, Zompetta C, Fidler IJ, Andreeff M. Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors. Cancer Res. 2002;62(13):3603–8.PubMed

12.

Nakamura K, Ito Y, Kawano Y, Kurozumi K, Kobune M, Tsuda H, et al. Antitumor effect of genetically engineered mesenchymal stem cells in a rat glioma model. Gene Ther. 2004;11(14):1155–64. doi:10.1038/sj.gt.3302276.CrossRefPubMed

13.

Choi SA, Lee JY, Wang KC, Phi JH, Song SH, Song J, et al. Human adipose tissue-derived mesenchymal stem cells: characteristics and therapeutic potential as cellular vehicles for prodrug gene therapy against brainstem gliomas. Eur J Cancer. 2012;48(1):129–37. doi:10.1016/j.ejca.2011.04.033.CrossRefPubMed

14.

Sun XL, Xu ZM, Ke YQ, Hu CC, Wang SY, Ling GQ, et al. Molecular targeting of malignant glioma cells with an EphA2-specific immunotoxin delivered by human bone marrow-derived mesenchymal stem cells. Cancer Lett. 2011;312(2):168–77. doi:10.1016/j.canlet.2011.07.035.CrossRefPubMed

15.

Maestroni GJ, Hertens E, Galli P. Factor(s) from nonmacrophage bone marrow stromal cells inhibit Lewis lung carcinoma and B16 melanoma growth in mice. Cell Mol Life Sci: CMLS. 1999;55(4):663–7.CrossRefPubMed

16.

Sun B, Roh KH, Park JR, Lee SR, Park SB, Jung JW, et al. Therapeutic potential of mesenchymal stromal cells in a mouse breast cancer metastasis model. Cytotherapy. 2009;11(3):289–98. doi:10.1080/14653240902807026. 1 p following 98.CrossRefPubMed

17.

Ren C, Kumar S, Chanda D, Kallman L, Chen J, Mountz JD, et al. Cancer gene therapy using mesenchymal stem cells expressing interferon-beta in a mouse prostate cancer lung metastasis model. Gene Ther. 2008;15(21):1446–53. doi:10.1038/gt.2008.101.CrossRefPubMedPubMedCentral

18.

Kidd S, Caldwell L, Dietrich M, Samudio I, Spaeth EL, Watson K, et al. Mesenchymal stromal cells alone or expressing interferon-beta suppress pancreatic tumors in vivo, an effect countered by anti-inflammatory treatment. Cytotherapy. 2010;12(5):615–25. doi:10.3109/14653241003631815.CrossRefPubMed

19.

Zischek C, Niess H, Ischenko I, Conrad C, Huss R, Jauch KW, et al. Targeting tumor stroma using engineered mesenchymal stem cells reduces the growth of pancreatic carcinoma. Ann Surg. 2009;250(5):747–53. doi:10.1097/SLA.0b013e3181bd62d0.CrossRefPubMed

20.

Lee HJ, Lee EK, Lee KJ, Hong SW, Yoon Y, Kim JS. Ectopic expression of neutrophil gelatinase-associated lipocalin suppresses the invasion and liver metastasis of colon cancer cells. Int J Cancer J Int Du Cancer. 2006;118(10):2490–7. doi:10.1002/ijc.21657.CrossRef

21.

Lim R, Ahmed N, Borregaard N, Riley C, Wafai R, Thompson EW, et al. Neutrophil gelatinase-associated lipocalin (NGAL) an early-screening biomarker for ovarian cancer: NGAL is associated with epidermal growth factor-induced epithelio-mesenchymal transition. Int J Cancer J Int du cancer. 2007;120(11):2426–34. doi:10.1002/ijc.22352.CrossRef

22.

Tong Z, Kunnumakkara AB, Wang H, Matsuo Y, Diagaradjane P, Harikumar KB, et al. Neutrophil gelatinase-associated lipocalin: a novel suppressor of invasion and angiogenesis in pancreatic cancer. Cancer Res. 2008;68(15):6100–8. doi:10.1158/0008-5472.CAN-08-0540.CrossRefPubMedPubMedCentral

23.

Halabian R, Tehrani HA, Jahanian-Najafabadi A, Habibi RM. Lipocalin-2-mediated upregulation of various antioxidants and growth factors protects bone marrow-derived mesenchymal stem cells against unfavorable microenvironments. Cell Stress Chaperones. 2013;18(6):785–800. doi:10.1007/s12192-013-0430-2.CrossRefPubMedPubMedCentral

24.

Bolignano D, Donato V, Lacquaniti A, Fazio MR, Bono C, Coppolino G, et al. Neutrophil gelatinase-associated lipocalin (NGAL) in human neoplasias: a new protein enters the scene. Cancer Lett. 2010;288(1):10–6. doi:10.1016/j.canlet.2009.05.027.CrossRefPubMed

25.

Mohammadzadeh M, Halabian R, Gharehbaghian A, Amirizadeh N, Jahanian-Najafabadi A, Roushandeh AM, et al. Nrf-2 overexpression in mesenchymal stem cells reduces oxidative stress-induced apoptosis and cytotoxicity. Cell Stress Chaperones. 2012;17(5):553–65. doi:10.1007/s12192-012-0331-9.CrossRefPubMedPubMedCentral

26.

Kucerova L, Altanerova V, Matuskova M, Tyciakova S, Altaner C. Adipose tissue–derived human mesenchymal stem cells mediated prodrug cancer gene therapy. Cancer Res. 2007;67:6304–13. doi:10.1158/0008-5472.CAN-06-4024.CrossRefPubMed

27.

Adil M, Belur L, Pearce TR, Levine RM, Tisdale AW, Sorenson BS, et al. PR_b functionalized stealth liposomes for targeted delivery to metastatic colon cancer. Biomater Sci. 2013;1(4):393–401. doi:10.1039/C2BM00128D.CrossRef

28.

Moritake S, Taira S, Ichiyanagi Y, Morone N, Song SY, Hatanaka T, et al. Functionalized nano-magnetic particles for an in vivo delivery system. J Nanosci Nanotechnol. 2007;7(3):937–44.CrossRefPubMed

29.

Lu RM, Chen MS, Chang DK, Chiu CY, Lin WC, Yan SL, et al. Targeted drug delivery systems mediated by a novel Peptide in breast cancer therapy and imaging. PLoS One. 2013;8(6):e66128. doi:10.1371/journal.pone.0066128.CrossRefPubMedPubMedCentral

30.

Li EM, Xu LY, Cai WJ, Xiong HQ, Shen ZY, Zeng Y. Functions of neutrophil gelatinase-associated lipocalin in the esophageal carcinoma cell line SHEEC. Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao Acta Biochim Biophys Sin. 2003;35(3):247–54.PubMed

31.

Venkatesha S, Hanai J, Seth P, Karumanchi SA, Sukhatme VP. Lipocalin 2 antagonizes the proangiogenic action of ras in transformed cells. Mol Cancer Res : MCR. 2006;4(11):821–9. doi:10.1158/1541-7786.MCR-06-0110.CrossRefPubMed

32.

Yang J, McNeish B, Butterfield C, Moses MA. Lipocalin 2 is a novel regulator of angiogenesis in human breast cancer. FASEB J : Off Publ Fed Am Soc Exp Biol. 2013;27(1):45–50. doi:10.1096/fj.12-211730.CrossRef

Title: Targeting delivery of lipocalin 2-engineered mesenchymal stem cells to colon cancer in order to inhibit liver metastasis in nude mice
Authors: Mozhgan Dehghan Harati
Fatemeh Amiri
Fatemeh Jaleh
Ahmad Mehdipour
Mitra Dehghan Harati
Sedigheh Molaee
Marzieh Bahadori
Mohammad Ali Shokrgozar
Mohammad Ali Jalili
Mehryar Habibi Roudkenar
Publication date: 01-08-2015
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 8/2015
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-015-3277-6

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Home
Congress Coverage
Clinical Collections
- Advances in Alzheimer’s
About Springer Medicine
Key Specialties